The phase 3 ROSELLA study found that adding relacorilant (Lifyorli) to nab-paclitaxel (Abraxane) improves survival for patients with platinum-resistant ovarian cancer. Based on these results, the combination was approved by the U.S. Food and Drug Administration in March 2026 and is now recommended in NCCN treatment guidelines.
The study showed that patients receiving the combination had a 35% lower risk of death compared to chemotherapy alone. Median overall survival increased to 16.0 months versus 11.9 months, and patients also experienced longer time before disease progression (6.5 months vs. 5.5 months). The benefit was seen across different patient groups, including those who had prior treatments such as PARP inhibitors.
The trial included patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who had disease progression within six months of platinum therapy. While side effects were more common in the combination group, they were generally manageable and included fatigue, nausea, and low blood counts. No treatment-related deaths or adrenal insufficiency cases were reported.
Overall, the results suggest this combination offers a more effective treatment option for a difficult-to-treat form of ovarian cancer.